Mazor Robotics Ltd., together with its subsidiaries, engages in the development, production, and marketing of medical devices for supporting surgical procedures in the fields of orthopedics and neurosurgery in the United States and internationally. It operates in the field of computer assisted surgery that enable the use of surgical instruments with high precision and minimal invasiveness and that simplifies complex surgical procedures. The company's surgical robotic-guidance systems and complementary products are used to conduct spine and brain procedures in an accurate and secure manner. It also offers Mazor X, a renaissance system and its accessories are used in spine surgeries, including fusion, correction of spinal deformities, biopsy collection, tumor excision, and cement augmentations. The company was formerly known as Mazor Surgical Technologies Ltd. and changed its name to Mazor Robotics Ltd. in 2010. Mazor Robotics Ltd. was founded in 2000 and is based in Caesarea, Israel.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MZOR
CUSIPN/A
Phone972-4618-7101
Debt
Debt-to-Equity RatioN/A
Current Ratio7.96
Quick Ratio7.44
Price-To-Earnings
Trailing P/E Ratio-121.48
Forward P/E Ratio1,223.00
P/E GrowthN/A
Sales & Book Value
Annual Sales$64.95 million
Price / Sales24.79
Cash FlowN/A
Price / CashN/A
Book Value$4.46 per share
Price / Book13.71
Profitability
EPS (Most Recent Fiscal Year)($0.50)
Net Income$-12,410,000.00
Net Margins-12.14%
Return on Equity-8.08%
Return on Assets-6.91%
Miscellaneous
Employees204
Outstanding Shares26,330,000
Market Cap$1,584.95
Mazor Robotics (NASDAQ:MZOR) Frequently Asked Questions
What is Mazor Robotics' stock symbol?
Mazor Robotics trades on the NASDAQ under the ticker symbol "MZOR."
How were Mazor Robotics' earnings last quarter?
Mazor Robotics Ltd - (NASDAQ:MZOR) released its earnings results on Monday, May, 14th. The medical instruments supplier reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.04) by $0.02. The medical instruments supplier had revenue of $15.51 million for the quarter, compared to analysts' expectations of $15.13 million. Mazor Robotics had a negative net margin of 12.14% and a negative return on equity of 8.08%. Mazor Robotics's revenue for the quarter was up 32.3% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.08) EPS. View Mazor Robotics' Earnings History.
When is Mazor Robotics' next earnings date?
What price target have analysts set for MZOR?
5 brokers have issued 1 year target prices for Mazor Robotics' shares. Their forecasts range from $36.00 to $67.00. On average, they expect Mazor Robotics' share price to reach $55.50 in the next twelve months. This suggests that the stock has a possible downside of 9.2%. View Analyst Ratings for Mazor Robotics.
What is the consensus analysts' recommendation for Mazor Robotics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mazor Robotics in the last year. There are currently 2 sell ratings, 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
What are Wall Street analysts saying about Mazor Robotics stock?
Here are some recent quotes from research analysts about Mazor Robotics stock:
- 1. According to Zacks Investment Research, "Mazor Robotics Ltd. is engaged in the development, production and marketing of medical devices for surgical procedures in the fields of orthopedics and neurosurgery. It offers Renaissance(TM), a surgical robotic system to conduct spine surgeries with less radiation. The company operates in the United States, Eastern Europe, Western Europe and Asia. Mazor Robotics Ltd. is based in Caesarea, Israel. " (7/18/2018)
- 2. Needham & Company LLC analysts commented, "MZOR beat consensus revenue and met consensus EPS. We estimate that MZOR placed 14 systems in 1Q18, which is down sequentially from 24 in 4Q17 and below our estimate of 15. MZOR plans to integrate the Mazor X with MDT’s StealthStation navigation system by the end of 2018. But we don’t expect this to have a material impact on sales until 2019 and in the meantime we think the Mazor X remains at a disadvantage to GMED’s ExcelsiusGPS which already offers navigation. MZOR’s recurring revenue was stronger than expected and we suspect that this was helped by additional MDT stocking orders that are unlikely to be sustained for the remainder of the year. As a result, we maintain our Underperform rating." (5/14/2018)
Who are some of Mazor Robotics' key competitors?
Some companies that are related to Mazor Robotics include Hill-Rom (HRC), ICU Medical (ICUI), Globus Medical (GMED), Insulet (PODD), Haemonetics (HAE), Penumbra (PEN), Cantel Medical (CMD), Novocure (NVCR), Merit Medical Systems (MMSI), NuVasive (NUVA), Irhythm Technologies (IRTC), Nevro (NVRO), Glaukos (GKOS), Luminex (LMNX) and Tandem Diabetes Care (TNDM).
Who are Mazor Robotics' key executives?
Mazor Robotics' management team includes the folowing people:
- Mr. Ori Hadomi, CEO & Director (Age 51)
- Mr. Eliyahu Zehavi, Co-Founder & Exec. VP of Advanced Technologies (Age 63)
- Ms. Sharon Levita, CFO, VP of Bus. Operations & Company Sec. (Age 51)
- Mr. Christopher Prentice, Chief Commercial Officer (Age 48)
- Prof. Moshe Shoham, Co-Founder & CTO (Age 66)
Has Mazor Robotics been receiving favorable news coverage?
News articles about MZOR stock have been trending somewhat positive on Thursday, according to Accern Sentiment. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Mazor Robotics earned a news impact score of 0.20 on Accern's scale. They also assigned news articles about the medical instruments supplier an impact score of 46.36 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are Mazor Robotics' major shareholders?
Mazor Robotics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management (1.06%), Dorsey Wright & Associates (0.73%), American National Bank (0.02%), Atria Investments LLC (0.02%) and New England Research & Management Inc. (0.02%). View Institutional Ownership Trends for Mazor Robotics.
Which institutional investors are buying Mazor Robotics stock?
MZOR stock was bought by a variety of institutional investors in the last quarter, including Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management, Dorsey Wright & Associates, New England Research & Management Inc., American National Bank and Atria Investments LLC. View Insider Buying and Selling for Mazor Robotics.
How do I buy shares of Mazor Robotics?
Shares of MZOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mazor Robotics' stock price today?
One share of MZOR stock can currently be purchased for approximately $61.15.
How big of a company is Mazor Robotics?
Mazor Robotics has a market capitalization of $1.58 billion and generates $64.95 million in revenue each year. The medical instruments supplier earns $-12,410,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Mazor Robotics employs 204 workers across the globe.
How can I contact Mazor Robotics?
Mazor Robotics' mailing address is 5 SHACHAM STREET NORTH INDUSTRIAL PARK, CAESAREA L3, 3088900. The medical instruments supplier can be reached via phone at 972-4618-7101 or via email at [email protected]
MarketBeat Community Rating for Mazor Robotics (NASDAQ MZOR)
MarketBeat's community ratings are surveys of what our community members think about Mazor Robotics and other stocks. Vote "Outperform" if you believe MZOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MZOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
